<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04434300</url>
  </required_header>
  <id_info>
    <org_study_id>2019-004884-32</org_study_id>
    <nct_id>NCT04434300</nct_id>
  </id_info>
  <brief_title>Subcutaneous Daptomycin in Healthy Volunteers (DAPTOSC)</brief_title>
  <acronym>DAPTOSC</acronym>
  <official_title>Comparison of the Pharmacokinetic and the Safety of Daptomycin Administered Subcutaneously Compared to the Intravenous Route : a Cross-over Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Caen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Caen</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Background:&#xD;
&#xD;
      Multidrug-resistant bacteria are a major public health problem worldwide, notably due to&#xD;
      excess mortality and an increase in the length of hospital stay. Antibiotics that can be used&#xD;
      to treat these infections are limited. Daptomycin is one of the most widely used antibiotics&#xD;
      for the treatment of infections with gram-positive bacteria, such as methicillin-resistant&#xD;
      Staphylococcus aureus (MRSA). However, it is only administered intravenously (IV). It is&#xD;
      therefore interesting to find new routes of administration in order to widen the&#xD;
      possibilities of using daptomycin, especially in people who have difficulties with the venous&#xD;
      approach.&#xD;
&#xD;
      Methods/design:&#xD;
&#xD;
      In a randomized, single blinded, crossover, noninferiority study in the CHU of Caen, the&#xD;
      investigators aim to demonstrate the pharmacokinetic bioequivalence between the subcutaneous&#xD;
      and the intravenous route of daptomycin in healthy volunteers. They will conclude the&#xD;
      bioequivalence if the confidence interval of the area under the curve obtained is entirely&#xD;
      within the interval [80% - 125%].&#xD;
&#xD;
      Discussion:&#xD;
&#xD;
      This clinical trial could, if bioequivalence is demonstrated, lead to the completion of a&#xD;
      clinical trial in infected patients in order to assess the efficacy and safety of daptomycin&#xD;
      by the subcutaneous route.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 15, 2020</start_date>
  <completion_date type="Anticipated">June 2022</completion_date>
  <primary_completion_date type="Anticipated">October 15, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
    <masking_description>Subcutaneous administration of daptomycin and placebo will be done blind to the participant. Given the yellow coloration of daptomycin, a masking of the pockets of daptomycin and NaCl will be carried out with a pocket cover and an opaque tube will be used for the administration</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>daptomycin dosage after intravenous route</measure>
    <time_frame>before injection</time_frame>
    <description>measurement of daptomycin blood concentration after intravenous route</description>
  </primary_outcome>
  <primary_outcome>
    <measure>daptomycin dosage after intravenous route</measure>
    <time_frame>30 minutes after injection</time_frame>
    <description>measurement of daptomycin blood concentration after intravenous route</description>
  </primary_outcome>
  <primary_outcome>
    <measure>daptomycin dosage after intravenous route</measure>
    <time_frame>1 hours after injection</time_frame>
    <description>measurement of daptomycin blood concentration after intravenous route</description>
  </primary_outcome>
  <primary_outcome>
    <measure>daptomycin dosage after intravenous route</measure>
    <time_frame>1,50 hours after injection</time_frame>
    <description>measurement of daptomycin blood concentration after intravenous route</description>
  </primary_outcome>
  <primary_outcome>
    <measure>daptomycin dosage after intravenous route</measure>
    <time_frame>2 hours after injection</time_frame>
    <description>measurement of daptomycin blood concentration after intravenous route</description>
  </primary_outcome>
  <primary_outcome>
    <measure>daptomycin dosage after intravenous route</measure>
    <time_frame>3 hours after injection</time_frame>
    <description>measurement of daptomycin blood concentration after intravenous route</description>
  </primary_outcome>
  <primary_outcome>
    <measure>daptomycin dosage after intravenous route</measure>
    <time_frame>4 hours after injection</time_frame>
    <description>measurement of daptomycin blood concentration after intravenous route</description>
  </primary_outcome>
  <primary_outcome>
    <measure>daptomycin dosage after intravenous route</measure>
    <time_frame>8 hours after injection</time_frame>
    <description>measurement of daptomycin blood concentration after intravenous route</description>
  </primary_outcome>
  <primary_outcome>
    <measure>daptomycin dosage after intravenous route</measure>
    <time_frame>10 hours after injection</time_frame>
    <description>measurement of daptomycin blood concentration after intravenous route</description>
  </primary_outcome>
  <primary_outcome>
    <measure>daptomycin dosage after intravenous route</measure>
    <time_frame>24 hours after injection</time_frame>
    <description>measurement of daptomycin blood concentration after intravenous route</description>
  </primary_outcome>
  <primary_outcome>
    <measure>daptomycin dosage after subcutaneous route</measure>
    <time_frame>before injection</time_frame>
    <description>measurement of daptomycin blood concentration after subcutaneous route</description>
  </primary_outcome>
  <primary_outcome>
    <measure>daptomycin dosage after subcutaneous route</measure>
    <time_frame>30 minutes after injection</time_frame>
    <description>measurement of daptomycin blood concentration after subcutaneous route</description>
  </primary_outcome>
  <primary_outcome>
    <measure>daptomycin dosage after subcutaneous route</measure>
    <time_frame>1 hours after injection</time_frame>
    <description>measurement of daptomycin blood concentration after subcutaneous route</description>
  </primary_outcome>
  <primary_outcome>
    <measure>daptomycin dosage after subcutaneous route</measure>
    <time_frame>1.50 hours after injection</time_frame>
    <description>measurement of daptomycin blood concentration after subcutaneous route</description>
  </primary_outcome>
  <primary_outcome>
    <measure>daptomycin dosage after subcutaneous route</measure>
    <time_frame>2 hours after injection</time_frame>
    <description>measurement of daptomycin blood concentration after subcutaneous route</description>
  </primary_outcome>
  <primary_outcome>
    <measure>daptomycin dosage after subcutaneous route</measure>
    <time_frame>3 hours after injection</time_frame>
    <description>measurement of daptomycin blood concentration after subcutaneous route</description>
  </primary_outcome>
  <primary_outcome>
    <measure>daptomycin dosage after subcutaneous route</measure>
    <time_frame>4 hours after injection</time_frame>
    <description>measurement of daptomycin blood concentration after subcutaneous route</description>
  </primary_outcome>
  <primary_outcome>
    <measure>daptomycin dosage after subcutaneous route</measure>
    <time_frame>8 hours after injection</time_frame>
    <description>measurement of daptomycin blood concentration after subcutaneous route</description>
  </primary_outcome>
  <primary_outcome>
    <measure>daptomycin dosage after subcutaneous route</measure>
    <time_frame>10 hours after injection</time_frame>
    <description>measurement of daptomycin blood concentration after subcutaneous route</description>
  </primary_outcome>
  <primary_outcome>
    <measure>daptomycin dosage after subcutaneous route</measure>
    <time_frame>24 hours after injection</time_frame>
    <description>measurement of daptomycin blood concentration after subcutaneous route</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Local adverse events</measure>
    <time_frame>within the first 24hours after injection</time_frame>
    <description>Occurrence of local adverse events (pain, erythema, edema, necrosis)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Local adverse events</measure>
    <time_frame>3 days after the infusion</time_frame>
    <description>Occurrence of local adverse events (pain, erythema, edema, necrosis)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Local adverse events</measure>
    <time_frame>7 days after the infusion</time_frame>
    <description>Occurrence of local adverse events (pain, erythema, edema, necrosis)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Systemic adverse events</measure>
    <time_frame>within the first 24hours after injection</time_frame>
    <description>Occurrence of systemic adverse events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Systemic adverse events</measure>
    <time_frame>3 days after the infusion</time_frame>
    <description>Occurrence of systemic adverse events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Systemic adverse events</measure>
    <time_frame>7 days after the infusion</time_frame>
    <description>Occurrence of systemic adverse events</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">12</enrollment>
  <condition>Antibiotics</condition>
  <condition>Subcutaneous Injection</condition>
  <condition>Daptomycin</condition>
  <arm_group>
    <arm_group_label>Dapto SC-IV</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>First stage :&#xD;
Subcutaneous injection of daptomycin 10mg/kg&#xD;
Subcutaneous injection of placebo (physiological serum)&#xD;
Second stage :&#xD;
- Intravenous injection of daptomycin 10mg/kg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dapto IV-SC</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>First stage :&#xD;
- Intravenous injection of daptomycin 10mg/kg&#xD;
Second stage :&#xD;
Subcutaneous injection of daptomycin 10mg/kg&#xD;
Subcutaneous injection of placebo (physiological serum)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Daptomycin</intervention_name>
    <description>Compare the pharmacokinetic of subcutaneous (SC) and intravenous (IV) routes in the same patient.</description>
    <arm_group_label>Dapto SC-IV</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Daptomycin</intervention_name>
    <description>Compare the pharmacokinetic of subcutaneous (SC) and intravenous (IV) routes in the same patient.</description>
    <arm_group_label>Dapto IV-SC</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Healthy volunteer from 18 to 65 years old&#xD;
&#xD;
          -  Subject determined in good health by a doctor&#xD;
&#xD;
          -  Signature of free and informed consent&#xD;
&#xD;
          -  Affiliated to the French healthcare insurance&#xD;
&#xD;
          -  Fluent in French&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Active bacterial or viral infection&#xD;
&#xD;
          -  Immunocompromised&#xD;
&#xD;
          -  Body mass index &lt;20 or&gt; 30 kg / m2&#xD;
&#xD;
          -  Kidney failure with glomerular filtration rate &lt;90ml / min / m2 calculated according&#xD;
             to the CKD-EPI method&#xD;
&#xD;
          -  Known or suspected liver disease&#xD;
&#xD;
          -  Pregnant or lactating woman&#xD;
&#xD;
          -  Guardianship or curators&#xD;
&#xD;
          -  Any situation that could interfere with the self / hetero assessment of pain&#xD;
             (dementia, psychiatric disorders, for example)&#xD;
&#xD;
          -  Concomitant intake of myotoxic drugs (statins, fibrates, ciclosporin, for example)&#xD;
&#xD;
          -  Allergy or known side effects to daptomycin&#xD;
&#xD;
          -  Dermatological pathologies which may interfere with the subcutaneous injection&#xD;
             (eczema, psoriasis, etc.)&#xD;
&#xD;
          -  Localized tattoo or piercing on the abdomen which may interfere with the subcutaneous&#xD;
             injection or the evaluation of possible local effects of the injection&#xD;
&#xD;
          -  Parenteral exposure to daptomycin in the previous 30 days&#xD;
&#xD;
          -  The inclusion of the subject in another interventional research protocol (during the&#xD;
             present study and in the 3 months before inclusion).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Renaud Verdon, MD, PhD</last_name>
    <phone>+33231064709</phone>
    <email>verdon-r@chu-caen.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>CHU Caen</name>
      <address>
        <city>Caen</city>
        <state>Normandie</state>
        <zip>14000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Renaud Verdon, MD, PhD</last_name>
      <phone>+33231064709</phone>
      <email>verdon-r@chu-caen.fr</email>
    </contact>
    <investigator>
      <last_name>Aurélie Baldolli, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jocelyn Michon, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>April 29, 2020</study_first_submitted>
  <study_first_submitted_qc>June 15, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">June 16, 2020</study_first_posted>
  <last_update_submitted>July 28, 2021</last_update_submitted>
  <last_update_submitted_qc>July 28, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 30, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Daptomycin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

